ADA Advises Against Using Compounded GLP-1 RA Medications
Unregulated Weight Loss Drugs Raise Safety Concerns: ADA Issues Warning The American Diabetes Association (ADA) has issued a warning against the use of compounded medications designed to mimic popular GLP-1 receptor agonist (GLP-1 RA) and dual GIP/GLP-1 RA drugs. These medications, while often marketed as solutions for weight loss, are not FDA-approved and carry significant … Read more